AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33576820
Drug: Zinc gluconate
RxNorm normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zinc gluconate (50 mg)
Trial: 35194193
Drug: Anthracycline/cyclophosphamide‐taxane‐containing chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anthracycline/cyclophosphamide‐taxane‐containing chemotherapy (AC‐T)
Trial: 33814250
Drug: Corticocancellous (CC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticocancellous (CC) grafting
Trial: 32538252
Drug: MDMA (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDMA (100 mg MDMA-HCl)
Trial: 34666854
Drug: CGMP (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CGMP (20 g)
Trial: 34024503
Drug: Ketone monoester
RxNorm normalized name: Ketonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketone monoester supplement
Trial: 34137904
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg dextroamphetamine
Trial: 34836025
Drug: Tocovid (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocovid (200 mg twice daily)
Trial: 36267362
Drug: CONT-MMI (continuation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CONT-MMI (continuation of low-dose methimazole therapy at 2.5-5 mg/day)
Trial: 36267362
Drug: DISCONT-MMI (discontinuation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DISCONT-MMI (discontinuation of low-dose methimazole therapy)
Trial: 35793833
Drug: Lenzilumab (1800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenzilumab (1800 mg; three divided doses, q8h, within 24 hours)
Trial: 36223695
Drug: Subcutaneous trastuzumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous trastuzumab into the thigh
Trial: 36223695
Drug: Subcutaneous trastuzumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous trastuzumab into the abdominal wall (AW)
Trial: 32630031
Drug: Traditional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional therapy (5‐methyl‐tetrahydrofolate: 15 mg/day)
Trial: 32630031
Drug: 5 mL/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mL/day of Oxo with 300 μg folic acid (oxifolic)
Trial: 32630031
Drug: 5 mL/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mL/day of Oxo alone (magnesio+)
Trial: 33821693
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg intravenous Q4W
Trial: 33821693
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg subcutaneous Q4W
Trial: 33821693
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg intravenous Q12W
Trial: 33821693
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg subcutaneous Q12W
Trial: 33821693
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg intravenous Q12W
Trial: 33821693
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg subcutaneous Q12W
Trial: 34609773
Drug: Depatuxizumab mafodotin
RxNorm normalized name: Depatuxizumab mafodotin
DrugBank: Depatuxizumab mafodotin (DB11731)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Depatuxizumab mafodotin plus chemotherapy (temozolomide) in second-line therapy for EGFR-amplified recurrent WHO grade III/IV glioma
Trial: 34609773
Drug: Depatuxizumab mafodotin
RxNorm normalized name: Depatuxizumab mafodotin
DrugBank: Depatuxizumab mafodotin (DB11731)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Depatuxizumab mafodotin alone in second-line therapy for EGFR-amplified recurrent WHO grade III/IV glioma
Trial: 34609773
Drug: Depatuxizumab mafodotin
RxNorm normalized name: Depatuxizumab mafodotin
DrugBank: Depatuxizumab mafodotin (DB11731)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Depatuxizumab mafodotin plus chemoradiotherapy in first-line therapy for newly diagnosed WHO grade III/IV glioma
Trial: 34609773
Drug: Depatuxizumab mafodotin
RxNorm normalized name: Depatuxizumab mafodotin
DrugBank: Depatuxizumab mafodotin (DB11731)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Depatuxizumab mafodotin alone or plus chemotherapy/chemoradiotherapy
Trial: 32028023
Drug: Topical 5%
RxNorm normalized name: urea topical 5% topical lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 5% minoxidil gel
Trial: 32028023
Drug: Topical 0.2%
RxNorm normalized name: coal tar topical 0.2% topical soap
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.2% glyceryl trinitrate (GTN) cream
Trial: 34455583
Drug: Bamlanivimab (700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bamlanivimab (700 mg, 2,800 mg, or 7,000 mg)
Trial: 34971025
Drug: Tablet PC-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet PC-based dementia training (control)
Trial: 34836662
Drug: Clarithromycin-based standard
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin-based standard triple therapy (STT)
Trial: 34836662
Drug: Susceptibility-guided therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Susceptibility-guided therapy (SGT)
Trial: 32931024
Drug: Hyperthermic intraperitoneal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperthermic intraperitoneal chemotherapy (HIPEC) after interval debulking surgery (IDS)
Trial: 36083855
Drug: Leukotriene receptor
RxNorm normalized name: Leukotriene receptor antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leukotriene receptor antagonists (LTRA), specifically 10 mg of montelukast orally daily for 8 weeks.
Trial: 33284719
Drug: Mefenpyr‐diethyl (50 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mefenpyr‐diethyl (50 g a.i. ha‐1) applied on soybean plants
Trial: 32558469
Drug: Guided treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided treatment
Trial: 32111264
Drug: Fluoxetine 20
RxNorm normalized name: fluoxetine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 20 mg once daily for 6 months
Trial: 34307140
Drug: Intraperitoneal chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal chemotherapy group (sustained-release fluorouracil implants after standard D2 radical gastrectomy, followed by XELOX adjuvant chemotherapy)
Trial: 34307140
Drug: Intraperitoneal chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal chemotherapy group
Trial: 36454580
Drug: Tucatinib in
RxNorm normalized name: Product containing tucatinib in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tucatinib in combination with trastuzumab and capecitabine
Trial: 36454580
Drug: Placebo in
RxNorm normalized name: placebo INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in combination with trastuzumab and capecitabine
Trial: 35608017
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral minocycline 100 mg per day plus NBUVB phototherapy
Trial: 38662979
Drug: Vidofludimus calcium
RxNorm normalized name: Vidofludimus
DrugBank: Vidofludimus (DB15446)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vidofludimus calcium 45 mg
Trial: 38662979
Drug: Vidofludimus calcium
RxNorm normalized name: Vidofludimus
DrugBank: Vidofludimus (DB15446)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vidofludimus calcium 30 mg
Trial: 32493029
Drug: Dexmedetomidine 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 1.0 µg/kg
Trial: 33059613
Drug: Supplemental drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplemental drugs (iron folate)
Trial: 32744040
Drug: Baseline (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline (no treatments)
Trial: 35425986
Drug: Family Centered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family Centered Advance Care Planning for Teens with Cancer (FACE‐TC); 3 weekly sessions
Trial: 33661716
Drug: Control (licensed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (licensed tetanus, diphtheria, and acellular pertussis vaccine)
Trial: 33661716
Drug: Control (23-valent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (23-valent polysaccharide vaccine)
Trial: 35753838
Drug: EV71 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EV71 vaccine (separate administration)
Trial: 33356449
Drug: Various delivery
RxNorm normalized name: various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various delivery routes (oral, intradermal, intravenous)
Trial: 34551495
Drug: Tidal volume
RxNorm normalized name: VOLUME EXPANDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tidal volume of 4 ml/kg (group V1)
Trial: 34551495
Drug: Tidal volume
RxNorm normalized name: VOLUME EXPANDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tidal volume of 5 ml/kg (group V2)
Trial: 35288477
Drug: Liraglutide (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide (1.2 mg subcutaneous dose)
Trial: 33258354
Drug: Flesh-moistening paste
RxNorm normalized name: T8 Keto Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flesh-moistening paste applied topically twice daily for eight weeks
Trial: 33258354
Drug: Placebo applied
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo applied topically twice daily for eight weeks
Trial: 34330462
Drug: REPLENISH group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: REPLENISH group (target protein 1.8-2.2 g/kg/day)
Trial: 34330462
Drug: Standard group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard group (target protein 0.8-1.0 g/kg/day)
Trial: 35643253
Drug: Palliative standard-of-care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palliative standard-of-care treatment
Trial: 32535732
Drug: IL-6 inhibitors
RxNorm normalized name: IL-6
DrugBank: Human interleukin-6 (DB15060)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-6 inhibitors
Trial: 38802811
Drug: Standard-of-care treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care treatment
Trial: 32621644
Drug: Atorvastatin 20
RxNorm normalized name: atorvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 20 mg/d
Trial: 32434237
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate combined with levobupivacaine periarticular cocktail (20 mL of magnesium sulfate 250 mg + levobupivacaine 50 mg + triamcinolone 25 mg + 0.9% normal saline)
Trial: 33020647
Drug: LV20.19 CAR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LV20.19 CAR T cells (various doses)
Trial: 32753113
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose (bolus 10 mg kg−1)
Trial: 32753113
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose + maintenance (bolus 10 mg kg−1 + maintenance 1 mg kg−1 hr−1)
Trial: 32753113
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose (bolus 30 mg kg−1)
Trial: 32753113
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose + maintenance (bolus 30 mg kg−1 + maintenance 3 mg kg−1 hr−1)
Trial: 32572490
Drug: ePRO smartphone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ePRO smartphone app for RA (RA App v.1.0) with daily notifications regarding ePROs
Trial: 35352593
Drug: tolcapone 300
RxNorm normalized name: Tolcapone
DrugBank: Tolcapone (DB00323)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tolcapone 300 mg/day
Trial: 33033800
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg tadalafil
Trial: 34402044
Drug: Facemask oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Facemask oxygen (15 l.min-1)
Trial: 34402044
Drug: High-flow nasal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flow nasal oxygen (50 l.min-1)
Trial: 34378456
Drug: Laquinimod 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laquinimod 0.6 mg
Trial: 35487730
Drug: Atorvastatin 80
RxNorm normalized name: atorvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 80 mg daily
Trial: 33305662
Drug: Cabergoline combined
RxNorm normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cabergoline combined with hormone therapy standard schemes
Trial: 35791704
Drug: Dexpanthenol ampoule
RxNorm normalized name: Dexpanthenol
DrugBank: Dexpanthenol (DB09357)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dexpanthenol ampoule 250 mg/2 ml and biotin ampoule 5 mg/1 ml (Pars Behvarzan)
Trial: 35791704
Drug: Dexpanthenol ampoule
RxNorm normalized name: Dexpanthenol
DrugBank: Dexpanthenol (DB09357)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dexpanthenol ampoule 250 mg/2 ml and biotin ampoule 5 mg/1 ml (Bayer Company)
Trial: 35334797
Drug: Creatine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine supplementation (75 mg of Cr monohydrate·kg−1·day−1)
Trial: 34704430
Drug: Ceratonia siliqua
RxNorm normalized name: CERATONIA SILIQUA WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceratonia siliqua (Carob) capsules, 500 mg, taken daily for 90 days
Trial: 34704430
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E capsules, taken three times a day for 90 days
Trial: 35975547
Drug: High-dose AD109
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose AD109 (75/2.5 mg)
Trial: 35975547
Drug: Low-dose AD109
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose AD109 (37.5/2.5 mg)
Trial: 34321048
Drug: 3 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g/d whole meat GSM powder
Trial: 32546963
Drug: Apatinib (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib (750 mg daily from Day 9-21)
Trial: 38458796
Drug: Calcium channel
RxNorm normalized name: Calcium channel blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium channel blockers (CCB)
Trial: 32289853
Drug: Thrombin injection
RxNorm normalized name: factor IX / factor VII / factor X / protein C / protein S / prothrombin Injection
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombin injection
Trial: 32289853
Drug: Glue injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glue injection
Trial: 34641839
Drug: Multidisciplinary rehabilitation
RxNorm normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidisciplinary rehabilitation program (including occupational therapy and reintegration consultation)
Trial: 34238342
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese medicine (TCM) granules combined with chemotherapy
Trial: 32437567
Drug: Entecavir (ETV)
RxNorm normalized name: Entecavir
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Entecavir (ETV) 0.5 mg per day plus Biejia-Ruangan (BR) 2 g 3 times a day for 72 weeks
Trial: 32437567
Drug: Entecavir (ETV)
RxNorm normalized name: Entecavir
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Entecavir (ETV) 0.5 mg per day plus Biejia-Ruangan (BR)
Trial: 35413886
Drug: Loading dose
RxNorm normalized name: NUZYRA 7-Day Oral Pack including loading dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading dose of 1.5-g meropenem resolved in 30-ml saline given via central line for 30 min, followed by 0.75-g meropenem every 8 h for 30 min.
Trial: 35413886
Drug: Loading dose
RxNorm normalized name: NUZYRA 7-Day Oral Pack including loading dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading dose of 1.5-g meropenem.
Trial: 34441930
Drug: Immediate invasive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate invasive treatment strategy (<3 h)
Trial: 34441930
Drug: Early invasive
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early invasive treatment strategy (12–24 h)
Trial: 35667715
Drug: Cevira (hexaminolevulinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cevira (hexaminolevulinate photodynamic therapy)
Trial: 34351693
Drug: Intralesional tuberculin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional tuberculin immunotherapy
Trial: 33942655
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care therapies
Trial: 33665467
Drug: Personalized antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized antibiotic prescription feedback and evidence-based treatment guidelines including region-specific antibiotic resistance information, provided quarterly for two years.
Trial: 33665467
Drug: Personalized antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized antibiotic prescription feedback and evidence-based treatment guidelines.
Trial: 32579859
Drug: Conventional voice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional voice therapy
Trial: 33767062
Drug: Invasive strategy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Invasive strategy (e.g., percutaneous coronary intervention or coronary artery bypass graft)
Trial: 36444331
Drug: Atorvastatin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin therapy
Trial: 35588754
Drug: Single vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single vaccine regimen (Rotavac-Rotavac-Rotavac, Rotasiil-Rotasiil-Rotasiil)
Trial: 35588754
Drug: Single vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single vaccine regimen
Trial: 34625284
Drug: Anastrozole 1
RxNorm normalized name: anastrozole 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anastrozole 1 mg/day
Trial: 32627500
Drug: Naomaitai Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naomaitai Capsules
Trial: 32627500
Drug: Xiaoshuan Changrong
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xiaoshuan Changrong Capsules
Trial: 32627500
Drug: Angong Niuhuang
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angong Niuhuang Pills
Trial: 32627500
Drug: Naoxintong Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naoxintong Capsules
Trial: 32627500
Drug: Tongxinluo Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tongxinluo Capsules
Trial: 32627500
Drug: Naoxueshu Oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naoxueshu Oral Liquid
Trial: 32627500
Drug: Zhuyu Tongmai
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zhuyu Tongmai Capsules
Trial: 32627500
Drug: Yinxingye Tablets
RxNorm normalized name: Yinxingye
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yinxingye Tablets
Trial: 32627500
Drug: Compound Danshen
RxNorm normalized name: DANSHEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound Danshen Tablets
Trial: 33779002
Drug: S(+)-ibuprofen (S-IBU)
RxNorm normalized name: ibuprofen Oral Tablet [Ibu]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S(+)-ibuprofen (S-IBU)
Trial: 33779002
Drug: R(−)-ibuprofen (R-IBU)
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: R(−)-ibuprofen (R-IBU)
Trial: 32736660
Drug: Treatment-as-usual (control)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-as-usual (control)
Trial: 32658077
Drug: Neoadjuvant Stereotactic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant Stereotactic Body Radiation Therapy (SBRT) - 33 Gy in 5 fractions to gross tumor plus abutting vessel, with or without 25 Gy in 5 fractions to pancreatic head/body and celiac/superior mesenteric artery.
Trial: 32658077
Drug: Fractionated Chemoradiation
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractionated Chemoradiation - 50.4 Gy in 28 fractions to gross tumor, superior mesenteric/celiac arteries, and enlarged lymph nodes with concurrent bolus 5‐FU, leucovorin, oxaliplatin, irinotecan or gemcitabine/nab‐paclitaxel.
Trial: 32658077
Drug: Neoadjuvant Stereotactic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant Stereotactic Body Radiation Therapy (SBRT)
Trial: 34658960
Drug: Smartphone-based, multi-domain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smartphone-based, multi-domain cognitive training with gamified elements together with treatment as usual (TAU)
Trial: 38869034
Drug: Short-term dual
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term dual antiplatelet therapy (DAPT)
Trial: 35362188
Drug: Corticosteroid plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid plus glycyrrhizin (48-week stepwise dose reduction of methylprednisolone plus glycyrrhizin)
Trial: 32438483
Drug: Telemonitoring (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telemonitoring (daily body weight measurement, daily recording of HF symptoms, and personalised education)